niclosamide has been researched along with Cancer of Ovary in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cytotoxicity of niclosamide and its analogs in combination with carboplatin was demonstrated in 24 patient ascites samples." | 3.81 | Niclosamide Analogs for Treatment of Ovarian Cancer. ( Arend, RC; Buchsbaum, DJ; Chettiar, S; Gangrade, A; Hassmann, CJ; Hidalgo, B; Li, PK; Regan, N; Straughn, JM; Walters Haygood, CL, 2015) |
| "Knockdown of FXR1 or IGF2BP2 in ovarian cancer cells resulted in significantly reduced cell viability, adhesion, and migration." | 1.62 | Niclosamide's potential direct targets in ovarian cancer†. ( Bheemireddy, SR; Hayashi, K; MacLean, JA; Matzuk, M; Okuda, H; Plunkett, KN; Pru, C; Sekulovski, N; Yu, Z, 2021) |
| "Niclosamide is an "old" antihelminthic drug that uncouples mitochondria of intestinal parasites." | 1.43 | Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. ( Bai, MY; Chao, TK; Hu, TM; Huang, RL; Lai, HC; Lin, CK; Su, PH; Wang, YC; Weng, SJ, 2016) |
| "Ovarian cancer is the most lethal gynecologic malignancy, and there is an unmet clinical need to develop new therapies." | 1.43 | A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities. ( Chen, L; Deng, Y; Fan, J; Haydon, RC; He, TC; Hu, X; Liao, J; Liu, H; Luu, HH; Qi, H; Qiao, M; Wang, J; Wang, Z; Wei, Q; Yan, Z; Yu, X; Zhang, F; Zhang, J; Zou, Y, 2016) |
| "Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer mortality worldwide." | 1.43 | Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. ( Alvarez, RD; Arend, RC; Buchsbaum, DJ; Forero, A; Gangrade, A; Hidalgo, B; Katre, AA; Kurpad, C; Landen, CN; Li, PK; Li, Y; Londoño-Joshi, AI; Samant, RS; Straughn, JM; Yang, ES, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sekulovski, N | 1 |
| MacLean, JA | 1 |
| Bheemireddy, SR | 1 |
| Yu, Z | 1 |
| Okuda, H | 2 |
| Pru, C | 1 |
| Plunkett, KN | 1 |
| Matzuk, M | 1 |
| Hayashi, K | 2 |
| Arend, RC | 3 |
| Londoño-Joshi, AI | 2 |
| Samant, RS | 2 |
| Li, Y | 2 |
| Conner, M | 1 |
| Hidalgo, B | 3 |
| Alvarez, RD | 2 |
| Landen, CN | 2 |
| Straughn, JM | 3 |
| Buchsbaum, DJ | 3 |
| King, ML | 1 |
| Lindberg, ME | 1 |
| Stodden, GR | 1 |
| Ebers, SD | 1 |
| Johnson, A | 1 |
| Montag, A | 1 |
| Lengyel, E | 1 |
| MacLean Ii, JA | 1 |
| Walters Haygood, CL | 1 |
| Gangrade, A | 2 |
| Chettiar, S | 1 |
| Regan, N | 1 |
| Hassmann, CJ | 1 |
| Li, PK | 2 |
| Lin, CK | 1 |
| Bai, MY | 1 |
| Hu, TM | 1 |
| Wang, YC | 2 |
| Chao, TK | 1 |
| Weng, SJ | 1 |
| Huang, RL | 2 |
| Su, PH | 1 |
| Lai, HC | 2 |
| Deng, Y | 1 |
| Wang, Z | 1 |
| Zhang, F | 1 |
| Qiao, M | 1 |
| Yan, Z | 1 |
| Wei, Q | 1 |
| Wang, J | 1 |
| Liu, H | 1 |
| Fan, J | 1 |
| Zou, Y | 1 |
| Liao, J | 1 |
| Hu, X | 1 |
| Chen, L | 1 |
| Yu, X | 1 |
| Haydon, RC | 1 |
| Luu, HH | 1 |
| Qi, H | 1 |
| He, TC | 1 |
| Zhang, J | 1 |
| Katre, AA | 1 |
| Kurpad, C | 1 |
| Yang, ES | 1 |
| Forero, A | 1 |
| Yo, YT | 1 |
| Lin, YW | 1 |
| Balch, C | 1 |
| Chan, MW | 1 |
| Sytwu, HK | 1 |
| Chen, CK | 1 |
| Chang, CC | 1 |
| Nephew, KP | 1 |
| Huang, T | 1 |
| Yu, MH | 1 |
8 other studies available for niclosamide and Cancer of Ovary
| Article | Year |
|---|---|
Niclosamide's potential direct targets in ovarian cancer†.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Mice; Niclosamide; Ovarian Neoplas | 2021 |
Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
Topics: Animals; beta Catenin; Cell Proliferation; Cells, Cultured; Disease Progression; Drug Resistance, Ne | 2015 |
Niclosamide Analogs for Treatment of Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antinematodal Agents; Antineoplastic Agents; Ascites; beta Catenin | 2015 |
Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Drug | 2016 |
A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiparasitic Agents | 2016 |
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; C | 2016 |
Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Screeni | 2012 |